SCHEMBL19985025

SCHEMBL19985025

CC(=O)Nc1ccc(C(=O)N2CCN(C3=CCCC=C3)CC2c2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
PREP P48147 3/20 0.41
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ATM Q13315 1/20 0.39
P2RX7 Q99572 3/20 0.38
LMNA P02545 1/20 0.38
PKM P14618 1/20 0.38
AVPR1A P37288 1/20 0.37
TSHR P16473 1/20 0.37
EIF4A3 P38919 1/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19971958 0.80 MAPT (0.47) PREPALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL18286135 0.79 HSP90AA1 (0.52) ABCB1ABCG2PREPALDH1A1L3MBTL1
SCHEMBL18283321 0.74 PREP (0.62) PREPALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL18286158 0.74 PREP (0.58) PREPALDH1A1MEN1KMT2AATM
SCHEMBL19985024 0.73 SLC6A9 (0.43) P2RX7TSHREIF4A3HTT
SCHEMBL27261597 0.71 PREP (0.55) ABCB1ABCG2PREPALDH1A1MEN1
SCHEMBL19985023 0.69 SLC6A9 (0.47) MEN1KMT2AEIF4A3
SCHEMBL19971955 0.68 P2RX7 (0.44) ATMP2RX7EIF4A3MAPT
SCHEMBL7133590 0.65 RIPK1 (0.54) ABCB1ABCG2ALDH1A1L3MBTL1MEN1
SCHEMBL18286180 0.65 ALDH1A1 (0.67) PREPALDH1A1ATMLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180079730-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES SHIFA BIOMEDICAL CORP (US) 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079730-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES PCSK9, PCSK7, PCSK6 ABCB1 3187/4885ABCG2 2963/4885PREP 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.